MCL1 and acute myeloid leukemia: Interestingly, as a decrease in MCL1 levels is implicated in the SPHK1 inhibition mediated-apoptosis of AML cells, combination of sphingolipids targeted therapy with BH3 mimetics could be beneficial (58).